Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intel: NANS 2018: Positive Data Intensifies Spinal-Cord Stim's Big-Four Rivalry

Executive Summary

The market for spinal cord stimulation (SCS) systems, used for treating chronic debilitating pain, is expanding relentlessly, and companies like Abbott Laboratories, Medtronic, Boston Scientific and Nevro are all vying to gain more market share with their respective technologies. At this year's annual meeting of the North American Neuromodulation Society (NANS) in Las Vegas, physicians were presented with the latest clinical evidence backing these innovations. This article looks at the overall SCS market, discusses study findings presented at NANS and the latest innovations. It also provides insights from two established pain management specialists on factors they think will drive SCS technologies forward.

You may also be interested in...



Abbott Wins FDA Approval For 'Low Dose' Non-Rechargeable Spinal Cord Stimulator

Abbott won US FDA approval for its Proclaim XR spinal cord stimulator. The device offers lower-dose and recharge-free neurostimulation for patients with chronic pain with a battery life for up to 10 years.

Real-World Data Support Boston Scientific’s Personalized Spinal Cord Stimulation Therapy

Results of the PRO study of Boston Scientific’s Spectra WaveWriter spinal cord stimulator support the development of “all-in-one” spinal cord stimulation technology that delivers multiple waveforms and anatomical targeting for treating low back and/or leg pain.

Global Kinetics’ Personal KinetiGraph Identifies Parkinson’s Patients Suitable For Deep Brain Stimulation

A new study shows the Personal KinetiGraph wearable monitor can help clinicians identify the Parkinson’s disease patients most likely to benefit from device-assisted therapies, including deep brain stimulation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel